Welcome to our dedicated page for Adlai Nortye Ltd. SEC filings (Ticker: ANL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adlai Nortye Ltd. (NASDAQ: ANL) SEC filings page on Stock Titan provides access to the company’s public reports as a foreign private issuer, including Form 20-F annual reports and Form 6-K current reports. Adlai Nortye prepares its consolidated financial statements in accordance with IFRS as issued by the International Accounting Standards Board and presents its results in U.S. dollars, giving investors a standardized view of its clinical-stage biotechnology operations.
In its Form 6-K filings, the company reports unaudited financial information such as statements of operations, financial position, cash flows and changes in shareholders’ equity. These filings show that Adlai Nortye is a clinical-stage company with no reported revenue in the periods presented, and that its operating results are driven primarily by research and development and administrative expenses related to oncology drug development. They also disclose cash and restricted cash balances, interest-bearing bank borrowings, contract liabilities and accumulated deficits, helping readers assess liquidity and capital structure.
Beyond financial data, Adlai Nortye’s 6-Ks include narrative updates on its oncology pipeline, describing the status of programs such as Buparlisib (AN2025), AN4005, AN8025, AN9025, AN4035 and AN0025, as well as expectations for clinical milestones. Other filings detail governance matters, including adoption of the 2025 Share Incentive Plan, director resignations and appointments, committee composition and notices of shareholder meetings.
On Stock Titan, these filings are updated as they are posted to EDGAR, and AI-powered summaries can help explain key points in complex documents, from financial trends to pipeline disclosures and board changes. Users can review quarterly and semiannual financial updates, equity and incentive plan information, and other regulatory disclosures in one place when researching ANL stock and Adlai Nortye’s development trajectory.